On Monday, Intellia Therapeutics Inc (NASDAQ: NTLA) opened lower -11.90% from the last session, before settling in for the closing price of $8.07. Price fluctuations for NTLA have ranged from $8.03 to $28.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 15.68% over the past five years. Company’s average yearly earnings per share was noted 11.04% at the time writing. With a float of $97.42 million, this company’s outstanding shares have now reached $102.03 million.
Let’s look at the performance matrix of the company that is accounted for 403 employees. In terms of profitability, gross margin is 91.17%, operating margin of -923.1%, and the pretax margin is -896.77%.
Intellia Therapeutics Inc (NTLA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Intellia Therapeutics Inc is 5.89%, while institutional ownership is 90.14%. The most recent insider transaction that took place on Mar 04 ’25, was worth 6,104. In this transaction EVP, Chief Technical Officer of this company sold 679 shares at a rate of $8.99, taking the stock ownership to the 95,369 shares. Before that another transaction happened on Mar 04 ’25, when Company’s EVP, General Counsel sold 2,572 for $8.99, making the entire transaction worth $23,122. This insider now owns 111,925 shares in total.
Intellia Therapeutics Inc (NTLA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 11.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.47% during the next five years compared to -20.04% drop over the previous five years of trading.
Intellia Therapeutics Inc (NASDAQ: NTLA) Trading Performance Indicators
Check out the current performance indicators for Intellia Therapeutics Inc (NTLA). In the past quarter, the stock posted a quick ratio of 5.77. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.25, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -4.40 in one year’s time.
Technical Analysis of Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics Inc (NASDAQ: NTLA) saw its 5-day average volume 4.04 million, a positive change from its year-to-date volume of 3.32 million. As of the previous 9 days, the stock’s Stochastic %D was 8.22%. Additionally, its Average True Range was 0.75.
During the past 100 days, Intellia Therapeutics Inc’s (NTLA) raw stochastic average was set at 1.24%, which indicates a significant decrease from 4.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.14% in the past 14 days, which was higher than the 76.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.91, while its 200-day Moving Average is $16.87. Nevertheless, the first resistance level for the watch stands at $7.64 in the near term. At $8.16, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.49. If the price goes on to break the first support level at $6.78, it is likely to go to the next support level at $6.45. The third support level lies at $5.93 if the price breaches the second support level.
Intellia Therapeutics Inc (NASDAQ: NTLA) Key Stats
There are currently 103,517K shares outstanding in the company with a market cap of 736.01 million. Presently, the company’s annual sales total 57,880 K according to its annual income of -519,020 K. Last quarter, the company’s sales amounted to 12,870 K and its income totaled -128,900 K.
